<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="939">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05148923</url>
  </required_header>
  <id_info>
    <org_study_id>IGS202009</org_study_id>
    <nct_id>NCT05148923</nct_id>
  </id_info>
  <brief_title>ComPaRisOn of TwO DCCV algOrithms - RationaL Versus Maximum Fixed Energy</brief_title>
  <acronym>PROTOCOLENERGY</acronym>
  <official_title>Comparison of Two DCCV Algorithms - Rational Versus Maximum Fixed Energy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nemocnice AGEL Trinec-Podlesi a.s.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nemocnice AGEL Trinec-Podlesi a.s.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Direct current cardioversion (DCCV) is a widespread method to restore sinus rhythm in&#xD;
      patients with atrial fibrillation. It is a safe and effective method of treating atrial&#xD;
      fibrillation. In our study, we want to compare two algorithms. The rational one, with lower&#xD;
      initial energy and the second one with the maximum possible shock energy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart rhythm after DCCV</measure>
    <time_frame>one minute after DCCV</time_frame>
    <description>sinus rhythm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of DCCV</measure>
    <time_frame>two hours after DCCV</time_frame>
    <description>neurological complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin changes</measure>
    <time_frame>two hours after DCCV</time_frame>
    <description>none, skin redness, skin burns</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest pain</measure>
    <time_frame>day after DCCV</time_frame>
    <description>0-10 scale of pain severity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Rational energy algorithm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 J, 360 J, 360 J biphasic DCCV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maximum fixed energy algorithm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3x 360 J biphasic DCCV</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Direct current cardioversion (DCCV)</intervention_name>
    <description>DCCV is a safe and effective method of treating atrial fibrillation.</description>
    <arm_group_label>Maximum fixed energy algorithm</arm_group_label>
    <arm_group_label>Rational energy algorithm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have atrial fibrillation or atrial tachycardia.&#xD;
&#xD;
          2. Patients must be on therapeutic anticoagulation at least three weeks prior to DCCV or&#xD;
             undergo esophageal echocardiography to rule out intracardiac thrombus.&#xD;
&#xD;
          3. Patients come on an empty stomach.&#xD;
&#xD;
          4. Patients must be over 18 years of age.&#xD;
&#xD;
          5. Patients must provide verbal and written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Omitting oral anticoagulant treatment in the last three weeks.&#xD;
&#xD;
          2. Unclear time of onset of palpitations in acute patients without anticoagulation&#xD;
             therapy.&#xD;
&#xD;
          3. A different type of arrhythmia than atrial fibrillation or atrial tachycardia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucjan Rucki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nemocnice AGEL Trinec-Podlesi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucjan Rucki, MD</last_name>
    <phone>+420558304111</phone>
    <email>lucjan.rucki@npo.agel.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Otakar Jiravský, MD</last_name>
    <phone>+420558304111</phone>
    <email>otakar.jiravsky@npo.agel.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nemocnice AGEL Trinec-Podlesi</name>
      <address>
        <city>Trinec</city>
        <state>Česká Republika (Česko)</state>
        <zip>73961</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nemocnice AGEL Trinec-Podlesi a.s.</investigator_affiliation>
    <investigator_full_name>Lucjan Rucki</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>DCCV</keyword>
  <keyword>atrial fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

